within Pharmacolibrary.Drugs.ATC.L;

model L02BB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0295,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bicalutamide is a non-steroidal anti-androgen medication primarily used for the treatment of prostate cancer. It functions by blocking the action of male hormones (androgens) and is approved for use in combination with luteinizing hormone-releasing hormone analogues for advanced prostate cancer. Bicalutamide is approved and currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy male volunteers after oral administration.</p><h4>References</h4><ol><li><p>Cockshott, ID (2004). Bicalutamide: clinical pharmacokinetics and metabolism. <i>Clinical pharmacokinetics</i> 43(13) 855–878. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443130-00003&quot;>10.2165/00003088-200443130-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15509184/&quot;>https://pubmed.ncbi.nlm.nih.gov/15509184</a></p></li><li><p>Kim, KA, et al., &amp; Park, JY (2015). Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. <i>Clinica chimica acta; international journal of clinical chemistry</i> 438 7–11. DOI:<a href=&quot;https://doi.org/10.1016/j.cca.2014.08.006&quot;>10.1016/j.cca.2014.08.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25124867/&quot;>https://pubmed.ncbi.nlm.nih.gov/25124867</a></p></li><li><p>Cantarini, M, et al., &amp; Morris, T (2006). Pharmacokinetics of two novel bicalutamide formulations in healthy male volunteers. <i>Pharmacology</i> 77(4) 171–178. DOI:<a href=&quot;https://doi.org/10.1159/000094599&quot;>10.1159/000094599</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16847400/&quot;>https://pubmed.ncbi.nlm.nih.gov/16847400</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BB03;
